Global Tarceva (Roche/Chugai/Astellas) Drug Overview & Outlook 2017-2026

Dublin, July 05, 2019 (GLOBE NEWSWIRE) -- The "Tarceva" report has been added to ResearchAndMarkets.com's offering.

Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

EGFR is part of the ErbB pathway, which is hyperactivated or dysregulated in many cancers, thereby leading to uncontrolled cell growth. In particular, EGFR-activating mutations such as exon 19 deletion (del19) or exon 21 point mutation L858R have previously been identified as contributing to the promotion of tumor cell growth and blocking apoptosis in non-small cell lung cancer.

Tarceva reversibly inhibits the kinase activity of EGFR, and has higher binding affinity for EGFR del19 or exon 21 point mutation L858R mutations compared with wild-type receptors. This prevents the initiation of signaling cascades and results in the inhibition of EGFR-dependent proliferation.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Tarceva: Non-small cell lung cancer (NSCLC)

LIST OF FIGURES
Figure 1: Tarceva for non-small cell lung cancer - SWOT analysis
Figure 2: The authors drug assessment summary for Tarceva in non-small cell lung cancer
Figure 3: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES
Table 1: Tarceva drug profile
Table 2: Tarceva pivotal trial data in non-small cell lung cancer
Table 3: Tarceva ongoing late-phase clinical trials in non-small cell lung cancer
Table 4: Tarceva late-phase trial data in non-small cell lung cancer
Table 5: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Tarceva patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/1f4vyk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Lung Cancer Drugs , Skin Cancer Drugs, Pancreatic Cancer Drugs , Kidney Cancer Drugs